Subscribe to RSS
DOI: 10.1055/a-1990-2861
Facial Nerve Schwannoma Treatment with Stereotactic Radiosurgery (SRS) versus Resection followed by SRS: Outcomes and a Management Protocol

Abstract
Background Stereotactic radiosurgery (SRS) and resection are treatment options for patients with facial nerve schwannomas without mass effect.
Objective This article evaluates outcomes of patients treated with SRS versus resection + SRS.
Method We retrospectively compared 43 patients treated with SRS to 12 patients treated with resection + SRS. The primary study outcome was unfavorable combined endpoint, defined as worsening or new clinical symptoms, and/or tumor radiological progression. SRS (38.81 ± 5.3) and resection + SRS (67.14 ± 11.8) groups had similar clinical follow-ups.
Results At the time of SRS, the tumor volumes of SRS (mean ± standard error; 1.83 ± 0.35 mL) and resection + SRS (2.51 ± 0.75 mL) groups were similar. SRS (12.15 ± 0.08 Gy) and resection + SRS (12.16 ± 0.14 Gy) groups received similar radiation doses. SRS group (42/43, 98%) had better local tumor control than the resection + SRS group (10/12, 83%, p = 0.04). Most of SRS (32/43, 74%) and resection + SRS (10/12, 83%) group patients reached a favorable combined endpoint following SRS (p = 0.52). Considering surgical associated side effects, only 2/10 patients of the resection + SRS group reached a favorable endpoint (p < 0.001).
Patients of SRS group, who are > 34 years old (p = 0.02), have larger tumors (> 4 mL, 0.04), internal auditory canal (IAC) segment tumor involvement (p = 0.01) were more likely to reach an unfavorable endpoint. Resection + SRS group patients did not show such a difference.
Conclusion While resection is still needed for larger tumors, SRS offers better clinical and radiological outcomes compared to resection followed by SRS for facial schwannomas. Younger age, smaller tumors, and non-IAC situated tumors are factors that portend a favorable outcome.
Publication History
Received: 27 August 2022
Accepted: 24 November 2022
Accepted Manuscript online:
30 November 2022
Article published online:
30 December 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Mehta GU, Lekovic GP, Slattery WH. et al. Effect of anatomic segment involvement on stereotactic radiosurgery for facial nerve schwannomas: an international multicenter cohort study. Neurosurgery 2020; 88 (01) E91-E98
- 2 Rhoton Jr AL, Kobayashi S, Hollinshead WH. Nervus intermedius. J Neurosurg 1968; 29 (06) 609-618
- 3 Pathapati D, Barla K, Dayal M, Gati R, Lakota PK. Facial nerve schwannoma: the rare/great mimicker of vestibular schwannoma/neuroma. Indian J Radiol Imaging 2021; 31 (02) 510-513
- 4 Thai NLB, Mai NY, Vuong NL. et al. Treatment for vestibular schwannoma: Systematic review and single arm meta-analysis. Am J Otolaryngol 2022; 43 (02) 103337
- 5 Eshraghi AA, Oker N, Ocak E. et al. Management of facial nerve schwannoma: a multicenter study of 50 cases. J Neurol Surg B Skull Base 2019; 80 (04) 352-356
- 6 Tonetti D, Bhatnagar J, Lunsford LD. Quantitative analysis of movement of a cervical target during stereotactic radiosurgery using the Leksell Gamma Knife Perfexion. J Neurosurg 2012; 117 (Suppl): 211-216
- 7 Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (05) 1341-1346
- 8 Quesnel AM, Santos F. Evaluation and management of facial nerve schwannoma. Otolaryngol Clin North Am 2018; 51 (06) 1179-1192
- 9 Murai T, Kamata SE, Sato K. et al. Hypofractionated stereotactic radiotherapy for auditory canal or middle ear cancer. Cancer Contr 2016; 23 (03) 311-316